Pj. Sulak, ENDOMETRIAL CANCER AND HORMONE REPLACEMENT THERAPY - APPROPRIATE USE OF PROGESTINS TO OPPOSE ENDOGENOUS AND EXOGENOUS ESTROGEN, Endocrinology and metabolism clinics of North America, 26(2), 1997, pp. 399
Endometrial cancer is the most common gynecologic malignancy; it is es
timated for 1997 that 34,000 cases will be reported of which 6000 will
result in death. Many of these cases are preventable by identifying p
atients with known risk factors, utilizing simple outpatient endometri
al sampling techniques, and treating patients at risk with progestin t
herapy. Hormone replacement (in appropriate doses), using progestin al
one, or progestin and estrogen combined, depending on the endogenous h
ormonal status of the patient, can decrease the incidence of this mali
gnancy.